News & Events

Castle Biosciences’ DecisionDx-Melanoma Test Shown to be a Significant Predictor of Distant Metastasis in Elderly Patients with Melanoma

Friendswood, TX–March 20, 2017 Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that studies evaluating the prognostic performance and clinical impact of the DecisionDx®-Melanoma gene expression profile (GEP) test, including a cohort of elderly patients and four independent studies, were presented during the 70th Society of Surgical Oncology Annual Cancer Symposium (SSO) held in Seattle, WA from March 15-18. “We know that there is a decline in the rate of more »

Study Demonstrates that DecisionDx-Melanoma Test Improves Identification of High Risk Skin Melanoma When Used with AJCC Outcome Prediction Tool

GEP classification and AJCC predictions of risk (n=205)Friendswood, TX – January 23, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of results from a study comparing and combining risk prediction using DecisionDx®-Melanoma, the Company’s gene expression profile (GEP) test used to predict risk of metastasis in cutaneous melanoma (CM) patients, and the American Joint Committee on Cancer’s (AJCC’s) clinical staging system using the Individualized Melanoma Patient Outcome Prediction Tool. The AJCC more »

Castle Biosciences Announces Data Presentations at the Association for Molecular Pathology 2016 Annual Meeting with Gene Expression Profile Tests for Uveal and Cutaneous Melanoma

Friendswood, TX – November 14, 2016 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from studies evaluating clinical experience with gene expression profile (GEP) tests DecisionDx®-Melanoma and DecisionDx®-UM. In the studies, both GEP tests demonstrated a high technical success rate with robust, reproducible and reliable performance. The data were presented in poster sessions at the Association for Molecular Pathology (AMP) 2016 Annual Meeting, which was held more »

Castle Biosciences Announces Data Presentation at the Society for Melanoma Research 2016 Congress Demonstrating Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management

Friendswood, TX – November 10, 2016 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from a study evaluating the clinical impact of its gene expression profile (GEP) test DecisionDx®-Melanoma on patient management decisions. The test uses tumor biology to provide an individual risk of recurrence in cutaneous (skin) melanoma patients. The data were presented in a poster session at the Society for Melanoma Research 2016 Congress, more »

Gene Expression Profiling Can Influence Melanoma Management

Clinical Oncology News | October 5, 2016 | Ajai Raj | A gene expression profiling test that classifies cutaneous melanoma (CM) patients into high- or low-risk categories for metastasis has been found to influence clinical management of CM patients, according to a team of investigators at multiple institutions in the United States. Publishing in Current Medical Research and Opinion (2016;32[9]:1599-1604, PMID: 27210115), the investigators wrote that “the vast majority” of clinical changes implemented after the receipt of results from DecisionDx-Melanoma (Castle Biosciences), a 31-gene expression profiling more »

Older Entries »
Know Your Risk

DecisionDx-Melanoma

A new genomic test is designed to predict if your cancer is at high risk of spreading, based on your tumor’s biology. Watch Video
Talk to Your Doctor
Decide with your doctor if DecisionDx-Melanoma is right for you. Download PDF
Gene Test Validation